Werewolf Therapeutics/HOWL

$4.78

-2.05%
-
1D1W1MYTD1YMAX

About Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Ticker

HOWL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel Hicklin

Employees

46

Headquarters

Watertown, United States

HOWL Metrics

BasicAdvanced
$211M
Market cap
-
P/E ratio
-$1.09
EPS
-
Beta
-
Dividend rate
$211M
$8.19
$1.57
182K
6.707
23.598
33.52
-22.31%
-34.84%
-25.22%
12.993
1.785
1.792
-22.26%
34.31%

What the Analysts think about HOWL

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
161.51% upside
High $15.00
Low $9.00
$4.78
Current price
$12.50
Average price target

HOWL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,300% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$700K
-53.33%
Net income
-$16M
34.17%
Profit margin
-2,300%
187.5%

HOWL Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.75%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.23
-$0.33
-$0.39
-
Expected
-$0.42
-$0.39
-$0.43
-$0.35
-$0.37
Surprise
-66.82%
-41.74%
-23.89%
11.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Werewolf Therapeutics stock?

Werewolf Therapeutics (HOWL) has a market cap of $212M as of May 18, 2024.

What is the P/E ratio for Werewolf Therapeutics stock?

The price to earnings (P/E) ratio for Werewolf Therapeutics (HOWL) stock is 0 as of May 18, 2024.

Does Werewolf Therapeutics stock pay dividends?

No, Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders as of May 18, 2024.

When is the next Werewolf Therapeutics dividend payment date?

Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders.

What is the beta indicator for Werewolf Therapeutics?

Werewolf Therapeutics (HOWL) does not currently have a Beta indicator.

What is the Werewolf Therapeutics stock price target?

The target price for Werewolf Therapeutics (HOWL) stock is $12.5, which is 164.83% above the current price of $4.72. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Werewolf Therapeutics stock

Buy or sell Werewolf Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing